Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies

The Oncotarget findings suggest that MEKi induced an increased expression of tumor-associated antigens, which in combination with anti-tumor antibodies, generated a robust adaptive anti-tumor response that was sustained by immune checkpoint inhibition the

Read more